Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Cymbalista · SciRah

Researcher profile · Semantic Scholar

F. Cymbalista

Share profile

F. Cymbalista — researcher profile on SciRah

h-index: 38
Works: 204
Citations: 7,979

Most-cited papers

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
J. Sharman, M. Egyed, W. Jurczak, A. Skarbnik +25 more
2020The Lancet541 citations Open access
Semantic Scholar
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
I. Flinn, P. Hillmen, M. Montillo, Z. Nagy +21 more
2018Blood312 citations Open access
Semantic Scholar
Autoimmune haemolytic anaemia associated with COVID‐19 infection
Grégory Lazarian, A. Quinquenel, M. Bellal, Justine Siavellis +8 more
2020British Journal of Haematology292 citations Open access
Semantic Scholar
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.
P. Baliakas, S. Jeromin, M. Iskas, A. Puiggros +38 more
2019Blood213 citations Open access
Semantic Scholar
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
J. Sharman, M. Egyed, W. Jurczak, A. Skarbnik +23 more
2022Leukemia172 citations Open access
Semantic Scholar
TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
E. Campo, F. Cymbalista, P. Ghia, U. Jäger +4 more
2018Haematologica153 citations Open access
Semantic Scholar
Prevalence of BTK and PLCG2 mutations in a real‑life CLL cohort still on ibrutinib after three years: a FILO group study.
A. Quinquenel, L. Fornecker, R. Letestu, L. Ysebaert +14 more
2019Blood106 citations Open access
Semantic Scholar
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis
Jennifer R. Brown, J. Moslehi, M. Ewer, S. O'Brien +23 more
2018British Journal of Haematology88 citations Open access
Semantic Scholar
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
E. Parry, I. Leshchiner, R. Guièze, Connor Johnson +50 more
2023Nature Medicine79 citations Open access
Semantic Scholar
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations
W. Wierda, A. Rawstron, F. Cymbalista, X. Badoux +17 more
2021Leukemia78 citations Open access
Semantic Scholar
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
C. Herling, F. Cymbalista, Carolin Groß-Ophoff-Müller, J. Bahlo +23 more
2020Leukemia70 citations Open access
Semantic Scholar
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL).
J. Sharman, V. Banerji, L. Fogliatto, Y. Herishanu +24 more
2019Blood64 citations Open access
Semantic Scholar
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice
J. Gribben, F. Bosch, F. Cymbalista, C. Geisler +4 more
2018British Journal of Haematology59 citations
Semantic Scholar
Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN
J. Sharman, M. Egyed, W. Jurczak, A. Skarbnik +23 more
2023Blood48 citations Open access
Semantic Scholar
Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia
C. Bagacean, R. Letestu, C. Al-nawakil, S. Brichler +22 more
2021Blood Advances48 citations Open access
Semantic Scholar
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation
Grégory Lazarian, Shanye Yin, E. ten Hacken, T. Sewastianik +25 more
2021Cancer Cell44 citations Open access
Semantic Scholar
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription
J. Edelmann, K. Holzmann, E. Tausch, E. A. Saunderson +23 more
2019Haematologica39 citations Open access
Semantic Scholar
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)
A. Quinquenel, T. Aurran-Schleinitz, A. Clavert, F. Cymbalista +20 more
2020HemaSphere35 citations Open access
Semantic Scholar
Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis
J. Broséus, Sébastien Hergalant, Julia Vogt, E. Tausch +38 more
2023Nature Communications32 citations Open access
Semantic Scholar
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort
F. Bouclet, A. Calleja, M. Dilhuydy, L. Véronèse +22 more
2021Annals of Hematology32 citations
Semantic Scholar
Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
S. O'Brien, J. Byrd, P. Hillmen, S. Coutre +14 more
2019American journal of hematology/oncology32 citations Open access
Semantic Scholar
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
R. Letestu, Abdelmalek Dahmani, M. Boubaya, L. Baseggio +25 more
2020Leukemia24 citations Open access
Semantic Scholar
Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group
Damien Roos-Weil, F. Nguyen-Khac, S. Chevret, C. Touzeau +18 more
2018Genes, Chromosomes and Cancer21 citations
Semantic Scholar
The Affinity of Hemoglobin for Oxygen Is Not Altered During COVID-19
T. Gille, L. Sesé, É. Aubourg, E. Fabre +6 more
2021Frontiers in Physiology20 citations Open access
Semantic Scholar
Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma
Grégory Lazarian, C. Friedrich, A. Quinquenel, Julie Tran +17 more
2020Oncogene20 citations
Semantic Scholar
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
A. Michallet, M. Dilhuydy, F. Subtil, V. Rouillé +30 more
2019The Lancet Haematology20 citations Open access
Semantic Scholar
Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome
Daniela Steinbrecher, B. Jebaraj, C. Schneider, J. Edelmann +11 more
2018Leukemia and Lymphoma19 citations
Semantic Scholar
Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21
Rim Zaaboub, L. Vimeux, V. Contremoulins, F. Cymbalista +5 more
2022Blood Advances18 citations Open access
Semantic Scholar
The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.
Jennifer R. Brown, F. Cymbalista, J. Sharman, I. Jacobs +2 more
2018The Oncologist16 citations Open access
Semantic Scholar
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
A. Michallet, R. Letestu, M. Le Garff-Tavernier, C. Aanei +30 more
2020Blood12 citations Open access
Semantic Scholar
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
A. Michallet, R. Letestu, M. Le Garff-Tavernier, L. Campos +29 more
2023Blood Advances11 citations Open access
Semantic Scholar
Frontline treatment in CLL: the case for time-limited treatment.
V. Lévy, A. Delmer, F. Cymbalista
2021Hematology. American Society of Hematology. Education Program11 citations Open access
Semantic Scholar
Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization
Charline Moulin, F. Guillemin, T. Rémen, F. Bouclet +23 more
2021American journal of hematology/oncology11 citations Open access
Semantic Scholar
Impact of Low-Burden TP53 Mutations in the Management of CLL
Grégory Lazarian, F. Cymbalista, F. Baran-Marszak
2022Frontiers in Oncology9 citations Open access
Semantic Scholar
TP53 Mutations Detected by NGS Are a Major Clinical Risk Factor for Stratifying Mantle Cell Lymphoma
Grégory Lazarian, Lotfi Chemali, Merieme Bensalah, Carla Zindel +14 more
2025American journal of hematology/oncology7 citations Open access
Semantic Scholar
Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities
K. Stamatopoulos, Š. Pavlová, O. Al-Sawaf, T. Chatzikonstantinou +8 more
2024HemaSphere7 citations Open access
Semantic Scholar
Response to vaccination against SARS‐CoV‐2 in 168 patients with Waldenström macroglobulinaemia: A French Innovative Leukaemia Organization study
C. Tomowiak, V. Leblond, K. Laribi, M. Baron +9 more
2022British Journal of Haematology6 citations
Semantic Scholar
Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO)
Grégory Lazarian, M. Munger, A. Quinquenel, M. Dilhuydy +30 more
2021American journal of hematology/oncology6 citations Open access
Semantic Scholar
Characterisation of a new clinical presentation of chronic lymphocytic leukaemia: symptomatic bronchial involvement, a study from the FILO group
M. Nudel, F. Baran-Marszak, Jean-Baptiste Bossard, R. Dubois +15 more
2019British Journal of Haematology6 citations
Semantic Scholar
Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia
W. Wierda, A. Roberts, P. Ghia, Jennifer R. Brown +13 more
2018Blood6 citations Open access
Semantic Scholar
High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group
A. Quinquenel, L. Fornecker, R. Letestu, Carole Fleury +13 more
2018Blood6 citations
Semantic Scholar
Identification of the Axis β-Catenin–BTK in the Dynamic Adhesion of Chronic Lymphocytic Leukemia Cells to Their Microenvironment
Imane Mihoub, T. Rharass, S. Ouriemmi, Antonin Oudar +12 more
2023International Journal of Molecular Sciences5 citations Open access
Semantic Scholar
RPS15 and TP53 Co-Mutation Drives B Cell Malignancy through Altered Translation and MYC Activation in a Murine Model
Catherine Gutierrez, Tamara Ouspenskaia, D. Fu, Peyton Waddicor +27 more
20205 citations
Semantic Scholar
Genetic Determinants and Evolutionary History of Richter's Syndrome
E. Parry, R. Guièze, I. Leshchiner, D. Rosebrock +34 more
20205 citations Open access
Semantic Scholar
Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial.
I. Flinn, M. Montillo, Á. Illés, G. Étienne +14 more
2019Journal of Clinical Oncology5 citations
Semantic Scholar
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia
P. Feugier, T. Aurran, B. Mahé, R. Letestu +17 more
2018Haematologica5 citations Open access
Semantic Scholar
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group
A. Quinquenel, R. Letestu, M. Le Garff-Tavernier, Stéphane Morisset +38 more
2025EClinicalMedicine4 citations Open access
Semantic Scholar
Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States
S. Péloquin, F. Cymbalista, M. Dreyling, N. Shah +4 more
2024BMC Cancer4 citations Open access
Semantic Scholar
TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia
Grégory Lazarian, F. Theves, M. Hormi, R. Letestu +22 more
2022American journal of hematology/oncology4 citations Open access
Semantic Scholar
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
B. Eichhorst, T. Robak, E. Montserrat, P. Ghia +8 more
2020Annals of Oncology4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Delmer×16
Invite
A. Delmer — researcher profile on SciRah
P. Ghia×15
Invite
P. Ghia — researcher profile on SciRah
S. Stilgenbauer×13
Invite
S. Stilgenbauer — researcher profile on SciRah
R. Letestu×13
Invite
R. Letestu — researcher profile on SciRah

×13

Invite

P. Feugier — researcher profile on SciRah

Grégory Lazarian×12

Invite

Grégory Lazarian — researcher profile on SciRah

F. Nguyen-Khac×11

Invite

F. Nguyen-Khac — researcher profile on SciRah

S. Leprêtre×11

Invite

S. Leprêtre — researcher profile on SciRah

Invite

V. Leblond — researcher profile on SciRah

Invite

K. Laribi — researcher profile on SciRah

F. Baran-Marszak×10

Invite

F. Baran-Marszak — researcher profile on SciRah

M. Dilhuydy×10

Invite

M. Dilhuydy — researcher profile on SciRah